Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02633020.

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationAmgen, Inc.

• Primary IDCELIM-RCD-002
• Secondary IDsNCI-2016-00706, 2015-004063-36
• ClinicalTrials.gov IDNCT02633020